표적 DNA RNA 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 기술별, 용도별, 종류별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Targeted DNA RNA Sequencing Market Size, Share & Trends Analysis Report By Workflow (Pre-sequencing, Sequencing, Data Analysis), By Technology, By Application, By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,620,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,069,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,967,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

표적 DNA RNA 시퀀싱 시장 : 개요

세계의 표적 DNA RNA 시퀀싱 시장 규모는 2024년에 74억 달러로 추정되며, 2033년까지 345억 6,000만 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 CAGR 18.98%로 확대될 것으로 예상됩니다. 정밀의료의 이용 확대, 암 및 유전성 질환의 발생률 증가, 특정 유전자 및 유전체 영역의 심층 분석, 보다 비용 효율적이고 정밀한 시퀀싱 방법에 대한 수요로 인해 시장은 빠르게 성장하고 있습니다.

정밀진단 및 표적치료에 대한 수요 확대

암, 심장병, 유전성 질환 등의 질병 발생률이 증가함에 따라 특정 치료법을 진단하고 개발할 필요성이 높아지고 있으며, 이것이 시장 성장을 견인하고 있습니다. 표적화 시퀀싱을 통해 병원성 돌연변이를 조기에 식별할 수 있어 진단을 촉진하고 치료 옵션을 개선할 수 있습니다. 특히 항암화학요법만큼 많은 부작용을 유발하지 않는 표적치료로 치료할 수 있는 암종에서는 이 점이 매우 중요합니다.

또한, 표적 시퀀싱은 특히 종양학 및 희귀질환 분야에서 개인화된 최소침습 치료로의 전환을 촉진할 수 있습니다. 실용적인 유전자 돌연변이를 식별함으로써 임상의는 표준 화학요법이나 광범위한 치료와 비교하여 보다 효과적이고 독성이 낮은 표적 치료법을 선택할 수 있게 됩니다. 맞춤형 의료 실현, 독성 최소화, 환자 결과 개선 등의 능력은 임상, 연구, 제약 분야에서 표적 시퀀스의 활용을 지속적으로 촉진하고 의료 혁신과 시장 확대에 기여하는 주요 요인으로 작용하고 있습니다.

기술 발전과 비용 효율성으로 보급 가속화

차세대 시퀀싱 플랫폼, 농축 화학 기술, 자동화의 발전으로 표적 시퀀싱을 보다 빠르고 정확하게, 그리고 훨씬 더 낮은 비용으로 수행할 수 있게 되었습니다. 개선된 포집 키트, 하이스루풋 시스템, 고성능 시약 등의 혁신으로 처리 시간 및 처리 시간을 단축하여 병원, 연구소, 생명공학 기업에서의 응용을 지원하고 있습니다.

또한, 표적 염기서열은 선택된 유전자 영역에만 초점을 맞추기 때문에 전체 유전체 염기서열보다 더 깊은 커버리지와 희귀 돌연변이 검출 감도를 향상시켜 전체 유전체 염기서열보다 우수합니다. 낮은 데이터 분석 요구 사항, 낮은 스토리지 요구 사항, 비용 효율적인 워크플로우로 인해 일상적인 진단, 정밀의료, 대규모 유전체 프로그램 등의 분야에서 의료 서비스 제공자의 채택이 증가하고 있습니다. 이러한 효율성에 기반한 가치 제안이 시장 확대를 지속적으로 추진하고 있습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 표적 DNA RNA 시퀀싱 시장 : 변수, 동향, 범위

• 시장 개요/연관 전망
• 시장 규모와 성장률 전망
• 시장 역학
• 비즈니스 환경 분석
  • PESTLE 분석
  • Porter's Five Forces 분석

제4장 표적 DNA RNA 시퀀싱 시장 : 기술별 추정·동향 분석

• 표적 DNA RNA 시퀀싱 시장 : 변동 분석, 기술별(2023년·2033년)
• 차세대 시퀀싱(NGS)
• 기타

제5장 표적 DNA RNA 시퀀싱 시장 : 워크플로우별 추정·동향 분석

• 표적 DNA RNA 시퀀싱 시장 : 변동 분석, 워크플로우별(2023년·2033년)
• 프리 시퀀싱
• 시퀀싱
• 데이터 분석

제6장 표적 DNA RNA 시퀀싱 시장 : 용도별 추정·동향 분석

• 표적 DNA RNA 시퀀싱 시장 : 변동 분석, 용도별(2023년·2033년)
• 인간 생체 의학 연구
• 식물·동물 과학
• Drug Discovery
• 기타

제7장 표적 DNA RNA 시퀀싱 시장 : 종류별 추정·동향 분석

• 표적 DNA RNA 시퀀싱 시장 : 변동 분석, 종류별(2023년·2033년)
• DNA 기반 표적 시퀀싱
• RNA 기반 표적 시퀀싱

제8장 표적 DNA RNA 시퀀싱 시장 : 최종 용도별 추정·동향 분석

• 표적 DNA RNA 시퀀싱 시장 : 변동 분석, 최종 용도별(2023년·2033년)
• 학술·연구
• 병원·진료소
• 제약·바이오테크놀러지 기업
• 기타

제9장 표적 DNA RNA 시퀀싱 시장 : 지역별 추정·동향 분석

• 표적 DNA RNA 시퀀싱 시장 : 시장 점유율 : 지역별(100만 달러, 2024년·2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 표적 DNA RNA 시퀀싱 시장(2021-2033년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 표적 DNA RNA 시퀀싱 시장(2021-2033년)
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 라틴아메리카의 표적 DNA RNA 시퀀싱 시장(2021-2033년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카의 표적 DNA RNA 시퀀싱 시장(2021-2033년)
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제10장 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업의 시장 포지션 분석(2024년)
• 기업 개요/리스트
  • Illumina
  • F. Hoffman-La Roche Ltd.
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Oxford Nanopore Technologies
  • PierianDx
  • Genomatix GmbH
  • DNASTAR, Inc.
  • Perkin Elmer, Inc.

KSM

영문 목차

영문목차

Targeted DNA RNA Sequencing Market Summary

The global targeted DNA RNA sequencing market size was estimated at USD 7.40 billion in 2024 and is projected to reach USD 34.56 billion by 2033, expanding at a CAGR of 18.98% from 2025 to 2033. The market is growing rapidly due to the increasing use of precision medicine, the rising incidence of cancer and genetic diseases, and the demand for more cost-efficient and highly accurate sequencing methodologies that enable the deep analysis of specific genes or genomic regions.

Growing Demand for Precision Diagnostics and Targeted Therapies

With the rising incidences of diseases such as cancer, heart diseases, and genetic disorders, the need to diagnose and develop specific treatments drives the market growth. In targeted sequencing, it is possible to identify pathogenic variations at an earlier stage in the process, which facilitates diagnosis and improves treatment options. This is particularly sensitive if the cancer type can be treated with targeted therapy that may not cause as many side effects as chemotherapy.

Moreover, targeted sequencing facilitates the transition to personalized, less invasive therapies, particularly in the fields of oncology and rare disease. By identifying actionable genetic mutations, clinicians can select targeted therapies that are both more effective and have lower toxicity compared to standard chemotherapy or broad-spectrum treatments. The capacity for individualized care, minimal toxicity, and improved patient outcomes continues to drive the use of targeted sequencing in the clinical, research, and pharmaceutical sectors, making it a major contributor to healthcare innovation and market expansion.

Technological Advancements and Cost Efficiency Accelerating Adoption

Advances in next-generation sequencing platforms, enrichment chemistry, and automation make targeted sequencing faster, more accurate, and significantly less costly. Innovations such as improved capture kits, high-throughput systems, and enhanced reagents are reducing processing and turnaround times, thereby supporting applications in hospitals, research laboratories, and biotech companies.

Moreover, targeted sequencing focuses on only selected gene regions, allowing for deeper coverage and increased sensitivity in detecting rarer variants, which is superior to whole-genome sequencing. Given that targeted sequencing has lower data analysis requirements, fewer storage needs, and cost-efficient workflows, it is increasingly chosen by healthcare providers in areas such as routine diagnostics, precision medicine, and large genomic programs. This value proposition, based on efficiencies, continues to drive market expansion.

Global Targeted DNA RNA Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global targeted DNA RNA sequencing market based on technology, workflow, application, type, end use, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• NGS
  • Method
  • Exome Sequencing
  • Enrichment Sequencing
  • Amplicon Sequencing
  • Others
  • Application
  • Cancer Gene Sequencing
  • Inherited Disease Screening
  • Drug Development
  • Forensic Genomics
  • 16S ribosomal RNA (rRNA) sequencing
• Others
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-sequencing
• Sequencing
• Data Analysis
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Human Biomedical Research
• Plant & Animal Sciences
• Drug Discovery
• Others
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• DNA Based Targeted Sequencing
• RNA Based Targeted Sequencing
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Technology
  • 1.2.2. Workflow
  • 1.2.3. Application
  • 1.2.4. Type
  • 1.2.5. End Use
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Targeted DNA RNA Sequencing Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Growing Demand for Precision Diagnostics and Targeted Therapies
    • 3.3.1.2. Technological Advancements and Cost Efficiency Accelerating Adoption
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. High Initial Capital Investment
• 3.4. Business Environment Analysis
  • 3.4.1. PESTLE Analysis
  • 3.4.2. PORTER'S Five Forces Analysis

Chapter 4. Targeted DNA RNA Sequencing Market: Technology Estimates & Trend Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Targeted DNA RNA Sequencing Market: Technology Movement Analysis, USD Million, 2023 & 2033
• 4.3. NGS
  • 4.3.1. NGS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Method Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.1. Exome Sequencing
      • 4.3.2.1.1. Exome Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.2. Enrichment Sequencing
      • 4.3.2.2.1. Enrichment Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.3. Amplicon Sequencing
      • 4.3.2.3.1. Amplicon Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.4. Others
      • 4.3.2.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Application Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.1. Cancer Gene Sequencing
      • 4.3.3.1.1. Cancer Gene Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.2. Inherited Disease Screening
      • 4.3.3.2.1. Inherited Disease Screening Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.3. Drug Development
      • 4.3.3.3.1. Drug Development Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.4. Forensic Genomics
      • 4.3.3.4.1. Forensic Genomics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.5. 16S Ribosomal RNA (rRNA)
      • 4.3.3.5.1. 16S Ribosomal RNA (rRNA) Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Others
  • 4.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Targeted DNA RNA Sequencing Market: Workflow Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Targeted DNA RNA Sequencing Market: Workflow Movement Analysis, USD Million, 2023 & 2033
• 5.3. Pre-sequencing
  • 5.3.1. Pre-sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Sequencing
  • 5.4.1. Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Data Analysis
  • 5.5.1. Data Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Targeted DNA RNA Sequencing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Targeted DNA RNA Sequencing Market: Application Movement Analysis, USD Million, 2023 & 2033
• 6.3. Human Biomedical Research
  • 6.3.1. Human Biomedical Research Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Plant & Animal Sciences
  • 6.4.1. Plant & Animal Sciences Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Drug Discovery
  • 6.5.1. Drug Discovery Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Targeted DNA RNA Sequencing Market: Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Targeted DNA RNA Sequencing Market: Type Movement Analysis, USD Million, 2023 & 2033
• 7.3. DNA Based Targeted Sequencing
  • 7.3.1. DNA Based Targeted Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. RNA Based Targeted Sequencing
  • 7.4.1. RNA Based Targeted Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Targeted DNA RNA Sequencing Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Targeted DNA RNA Sequencing Market: End Use Movement Analysis, USD Million, 2023 & 2033
• 8.3. Academic Research
  • 8.3.1. Academic Research Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Hospitals & Clinics
  • 8.4.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Pharma & Biotech Entities
  • 8.5.1. Pharma & Biotech Entities Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Targeted DNA RNA Sequencing Market: Regional Estimates & Trend Analysis

• 9.1. Targeted DNA RNA Sequencing Market Share, By Region, 2024 & 2033, USD Million
• 9.2. North America
  • 9.2.1. North America Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Competitive Scenario
    • 9.2.2.3. Regulatory Framework
    • 9.2.2.4. U.S. targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Competitive Scenario
    • 9.2.3.3. Regulatory Framework
    • 9.2.3.4. Canada targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Competitive Scenario
    • 9.2.4.3. Regulatory Framework
    • 9.2.4.4. Mexico targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. UK targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Germany targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. France targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Competitive Scenario
    • 9.3.5.3. Regulatory Framework
    • 9.3.5.4. Italy targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Competitive Scenario
    • 9.3.6.3. Regulatory Framework
    • 9.3.6.4. Spain targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Competitive Scenario
    • 9.3.7.3. Regulatory Framework
    • 9.3.7.4. Denmark targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Competitive Scenario
    • 9.3.8.3. Regulatory Framework
    • 9.3.8.4. Sweden targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Competitive Scenario
    • 9.3.9.3. Regulatory Framework
    • 9.3.9.4. Norway targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Japan targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. China targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. India targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Australia targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.4.6. Thailand
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Thailand targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.4.7. South Korea
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. South Korea targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Brazil targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Argentina targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
• 9.6. MEA
  • 9.6.1. MEA targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. South Africa targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Saudi Arabia targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Competitive Scenario
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. UAE targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Competitive Scenario
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Kuwait targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Illumina
    • 10.4.1.1. Participant's Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. F. Hoffman-La Roche Ltd.
    • 10.4.2.1. Participant's Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. QIAGEN
    • 10.4.3.1. Participant's Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. Thermo Fisher Scientific, Inc.
    • 10.4.4.1. Participant's Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. Bio-Rad Laboratories, Inc.
    • 10.4.5.1. Participant's Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. Oxford Nanopore Technologies
    • 10.4.6.1. Participant's Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. PierianDx
    • 10.4.7.1. Participant's Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. Genomatix GmbH
    • 10.4.8.1. Participant's Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. DNASTAR, Inc.
    • 10.4.9.1. Participant's Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Perkin Elmer, Inc.
    • 10.4.10.1. Participant's Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic Initiatives

관련자료